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Abstract
Purpose: R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone)
and R-CVP (rituximab with cyclophosphamide, vincristine and prednisone) have both been used
successfully in the treatment of patients with symptomatic follicular lymphoma (FL). No study has
compared the efficacy of the two treatment modalities and attempted to evaluate the role of
anthracyclines in the management of patients with FL. We conducted a meta-analysis of relevant
literature comparing the two treatment arms for FL with response being the final endpoint.
Patients and Methods: Two analyses were conducted: The first analysis compared R-CHOP to
R-CVP as frontline agents for the treatment of FL, and the second analysis included both untreated
and relapsed patients.
Results:  For both studies, R-CVP was superior to R-CHOP when evaluating for complete
response (CR). Odds ratios were 2.86 (95% CI, 1.81–4.51) in the first analysis and 1.48 (95% CI,
0.991–2.22) in the second analysis. However for overall response (CR+Partial response, PR), R-
CHOP was superior, with odds ratios of 5.45 (95% CI: 2.51 – 11.83) and 5.54 (95% CI: 2.69 –
11.40), for the first and second analyses, respectively.
Conclusion: R-CHOP and R-CVP protocols achieve excellent overall response. In patients with
known cardiac history, omission of anthracyclines is reasonable and R-CVP provides a competitive
CR rate. In younger patients with FL where cumulative cardio-toxicity may be of importance in the
long term and in whom future stem cell transplantation is an option, again R-CVP may be a more
appealing option.
Introduction
Follicular lymphomas (FL) are for the most part indolent
B-cell non-Hodgkin's lymphomas (B-NHL). Median sur-
vival is 9 to 11 years. Though FL initially responds to com-
bination and single-agent chemotherapy, the disease
ultimately relapses, with no plateau in the survival curve.
While cyclophosphamide, doxorubicin, vincristine and
prednisone (CHOP) [1] has been the initial chemother-
apy of choice for patients with aggressive NHL, no such
standard exists for patients with FL. Rituximab, a mono-
clonal antibody to CD20 antigen, is now commonly
added to chemotherapy regimens for FL. Rituximab has
been shown to have a favorable toxicity profile and to sig-
nificantly increase time to progression (TTP) and response
rates when used as a single agent in the treatment of symp-
tomatic FL [2]. Given such encouraging results, Czuczman
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et al. treated FL patients with a combination of rituximab
and CHOP (R-CHOP) [3]. Updated results showed that
the overall response rate was 100%; with 87% of patients
achieving a complete response or unconfirmed complete
response [4]. The median TTP and duration of response
was 82.3 months and 83.5 months, respectively. Hidde-
mann et al. reported a large prospective study comparing
R-CHOP directly to CHOP in patients with FL [5]. They
found that R-CHOP reduced the relative risk of treatment
failure by 60% and significantly prolonged time-to-treat-
ment-failure when compared to CHOP. Domingo-
Domenech et al. reported an overall response rate of 88%
in patients with relapsed FL who were treated with R-
CHOP [6]. Marcus et al. compared rituximab, cyclophos-
phamide, vincristine, prednisone (R-CVP) vs. CVP alone
and found an 81% response and 47% complete response
for R-CVP vs. 57% and 10% for CVP [7]. Based on the
existing literature, R-CHOP or R-CVP has become the
standard of care for the treatment of patients with symp-
tomatic advanced FL. Hainsworth et al.[8] used R-CVP or
R-CHOP, depending on the patients' cardiac co-morbidi-
ties, and showed a 93% response rate with 55% complete
remission and prolonged progression-free survival. How-
ever the authors did not isolate and compare the results
for R-CVP vs. R-CHOP. Moreover, one may be reasonably
concerned about the long-term risk of cumulative cardiac
toxicities when using doxorubicin (an anthracycline) in
patients with indolent lymphoma.
To our knowledge, there has been no head-to-head com-
parison of the efficacy of R-CVP vs. R-CHOP in patients
with FL. We do know that treatment with CHOP is signif-
icantly more expensive than with CVP [9]. Considering its
greater cost and its potential for causing long-term cardiac
toxicities, R-CHOP would therefore seem to be less attrac-
tive than R-CVP for treating FL. However, a significant dif-
ference in efficacy favoring R-CHOP-if such were shown
to exist might outweigh these factors. It is therefore impor-
tant to assess the relative efficacy of the two treatments.
Our first analysis reviewed the studies of frontline treat-
ment of patients with FL using either R-CVP or R-CHOP.
There are no published data illustrating R-CVP as a thera-
peutic modality for relapsed or previously treated patients
with FL, so it is impossible to compare responses to R-CVP
and R-CHOP in these patients. With this in mind, in a sec-
ond analysis we attempted to compare response rates for
R-CHOP and R-CVP in patients with FL irrespective of the
previous treatment status.
Patients and Methods
Data sources
Following the method of Falagas et al. [10], we did a sys-
tematic literature search involving Pubmed, the Cochrane
Central Register of Controlled Trials databases, and the
American Society of Hematology's (ASH) abstract collec-
tion, as well as references cited in relevant articles. Search
terms included "Follicular lymphoma", "Rituximab", "R-
CHOP", and "R-CVP."
Study selection
The articles were analyzed and relevant literature was fur-
ther evaluated. Published and unpublished data as well as
ASH abstracts were reviewed. No attempt was made to
judge studies' scientific merits (for example using the
QUOROM algorithm) [11]. A study was considered
acceptable if it prospectively evaluated the effectiveness of
R-CHOP or R-CVP, alone or in combination with another
treatment, for treating follicular lymphoma. To be consid-
ered eligible, the data from each treatment arm had to
have been reported separately and had to be extractable.
No restrictions were imposed on language, journal type,
or publication date. A total of seven studies were consid-
ered. Four of those met all inclusion criteria as studies of
frontline or re-treatment. Two of those four met the crite-
ria for the first analysis (frontline treatment alone).
Outcome
The primary goal of the analyses was to compare the
response rates of R-CVP and R-CHOP in the treatment of
patients with FL as frontline therapy or as re-treatment in
patients with relapsed disease. In every study patients
were classified as having no response, partial response
(PR) or complete response (CR). The definitions of tumor
response used in two of the studies were in accordance
with the International Working Group Criteria [12], while
one study used its own criteria for quantifying response.
For the present analysis we used three categories: Com-
plete Response: CR; Partial Response: PR, Total Response:
CR+PR, the last being the sum of the first two.
Other end points, such as time to treatment failure, dura-
tion of response and survival, were looked at, but not
directly compared due to inter-study variation in reporting.
Statistical analysis
Statistical analyses were performed using SPSS 14.0 (SPSS,
Chicago Ill). Patients' demographics and clinical charac-
teristics were expressed as proportions and compared
across treatments using 2-tailed Chi-squared tests. Treat-
ment efficacy was expressed as proportions of CR, PR and
CR+PR, and compared across treatments using 2-tailed
Chi-squared tests and odds ratios with 95% confidence
intervals (CI). P values < 0.05 were considered statistically
significant.
Results
Selected studies
In figure 1 is presented the flow diagram showing the
steps we took to identify relevant literature for our twoJournal of Hematology & Oncology 2009, 2:14 http://www.jhoonline.org/content/2/1/14
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analyses. After review of all available literature (all lan-
guages), three published studies were considered appro-
priate for the first analysis [5-7] and four for the second
[4-7]. Two studies involved randomized controlled trials
comparing treatment protocols of either R-CHOP vs.
CHOP or R-CVP vs. CVP. The other two studies were non-
randomized clinical trials which were designed to show
response, as previously described, by patients with FL
treated with R-CHOP. All four of the studies included R-
CVP or R-CHOP as the chemotherapeutic regimen to treat
FL and had relevant endpoints of CR or PR for all stages of
follicular lymphoma.
Patient characteristics
Demographics are shown in tables 1 and 2. The first anal-
ysis, in which R-CVP and R-CHOP are compared as front-
line chemotherapeutic agents, included the R-CHOP
study of Hiddemann et al. [5] and the R-CVP study of
Marcus et al. [7]. Both of these provided adequate patient
data; the comparison is shown in table 1. For our second
analysis, we compared R-CVP with R-CHOP as a frontline
or repeat treatment in patients with FL. Patient character-
istics in the second analysis are presented in table 2. Sex,
age and stage were the only patient characteristics
reported in all four studies. The studies by Hiddemann et
al. [5] and Domingo-Domenech et al. [6] included
patients with FL of stages 3 and 4 but did not show data
from each stage separately. Czuczman et al. [4] and Mar-
cus et al. [7] did not include patients of stage 1. To make
the data accurate and comparable across all four studies,
we reassigned patients into two broad stages: early stage
(Ann-Arbor stages I and II) and late stage (Ann-Arbor
stages III and IV). Combining the studies, there were 439
patients, and over 98% of these were late-stage
Treatment efficacy
The main characteristics of the four studies are shown in
table 3, where it is seen that the inclusion criteria were
similar across all studies. The R-CHOP and R-CVP arms
used identical medication dosing and treatment proto-
Article review process Figure 1
Article review process.
6000+ articles screened via pub med, ASH, and Cochrane 
library using “Follicular lymphoma”, “R-CVP”, “Rituximab”, 
and “R-CHOP”
6 articles and 1 abstract from published and unpublished 
data were reviewed and screened as potentially relevant 
1 ASH abstract and 1 prospective trial were excluded: 
Neither study differentiated efficacy of R-CHOP vs. R-CVP 
when compared to other treatment protocols for FL 
1 prospective trial evaluating treatment efficacy with R- 
CHOP  and R-CVP was excluded: It failed to separate 
results based on both treatment arms
4 studies were included:
A) 2 were prospective studies comparing CHOP or CVP 
with and without Rituximab in the frontline treatment of 
FL
B) 1  prospective trial evaluating responses to treatment 
with R-CHOP in patients with FL previously treated and 
untreated for the malignancy
C) 1 prospective trial evaluating responses to treatment 
with R-CHOP in patients with FL who have relapsed 
from previous treatments  Journal of Hematology & Oncology 2009, 2:14 http://www.jhoonline.org/content/2/1/14
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cols, with the exception that Adriamycin was not included
in the R-CVP regimen whereas it was used in the three R-
CHOP regimens. Three of the studies' definitions of CR
and PR conformed to the International Working Group
Criteria, and the study by Czuczman et al. used similar
characteristics.
Data from all four trials were collected and the response
rates (CR, PR, and CR+PR) yielded by R-CVP and R-CHOP
were summarized and evaluated. The first analysis com-
pared R-CHOP vs. R-CVP for the frontline treatment of
follicular lymphoma (Table 4). Patients who underwent
R-CVP therapy had a significantly higher chance of attain-
ing CR (41%) than patients treated with R-CHOP (20%)
(P  < 0.001). By contrast, significantly more patients
showed PR under R-CHOP (76%) than under R-CVP
(40%) (P  < 0.001), and R-CHOP showed better total
CR+PR (96% vs. 81%, p <0.001).
The second analysis revealed similar findings when com-
paring R-CVP to R-CHOP (Table 5) excepting that with
the additional studies on the R-CHOP side, the CR advan-
tage of R-CVP over R-CHOP (41% vs. 32%) was only mar-
ginally significant (p = 0.055).
These trends can also be seen in the odds ratios comparing
the two treatment modalities. For both studies, R-CVP was
superior to R-CHOP when evaluating only for complete
response. Odds ratios of 2.86 (95% CI: 1.81–4.51) in the
first analysis and 1.48 (95% CI: .991–2.22) in the second
analysis favored R-CVP over R-CHOP. However, for over-
all response (complete response + partial response), R-
CHOP was superior, with odds ratios of 5.45 (95% CI:
2.51 – 11.83) and 5.54 (95% CI: 2.69 – 11.40), for the
first and second analyses, respectively.
Discussion
Anthracyclines are always included in the treatment regi-
men for diffuse large cell lymphoma, but the role of
anthracyclines in treating patients with symptomatic FL is
not clear. Both R-CHOP and R-CVP are used frequently in
the management of symptomatic patients with FL. Hidde-
mann et al. [13] illustrated current advances in treatment
modalities for follicular lymphoma including the use of
chemotherapy, radio-therapy, monoclonal antibodies,
vaccine strategies, and stem cell transplants. Liu et al. [14]
had highlighted increased survival time over the past 25
years for those who have stage 4 FL with advances in treat-
ment options. It is still not clear whether addition of
anthracyclines in the therapy for FL confers any benefit.
In our analyses we tried to answer the question whether
addition of anthracyclines to the chemotherapeutic regi-
men improves response in patients with FL. To compare
the response rates between R-CHOP and R-CVP in a pro-
spective fashion would require a multi-year multicenter
trial involving a large number of patients. For example,
using nQuery 5.0, one can determine the sample size per
treatment group if the hypothesized treatment difference
is that obtained in the current study between R-CHOP and
Table 1: Patient Characteristics: Frontline Treatment with R-CVP and R-CHOP
Variable
(N; %)
R-CHOP
N = 223
Hiddemann et al [5]
R-CVP
N = 162
Marcus et al [7]
Total
N = 385
P-value
Sex M:88; 39.5%
F: 135; 60.5%
M: 88; 54.3%
F: 74; 45.7%
M: 176; 45.7%
F: 209; 54.3%
.004
Age>60 82; 36.8% 41; 25.3% 123; 31.9% .017
ECOG>1 16; 7.2% 4;2.5% 20; 5.2% .040
B-symptoms 80; 35.9% 65; 40.1% 145; 37.7% .396
Marrow involvement 136; 61.0% 103; 63.6% 239; 62.1% .605
IPI> 2 42; 18.8% 21; 13.0% 63; 16.4% .212
Stage I/II: 0; 0%
III/IV: 223; 100%
I/II: 2; 1.2%
III/IV: 160; 98.8%
I/II: 2; 0.5%
III/IV: 383; 99.5%
.342
Elevetaed LDH 51; 22.9% 39; 24.1% 90; 23.4% .783
Table 2: Patient Characteristics: Frontline and Re-treatment with R-CHOP and R-CVP
Variables (N; %) R-CHOP
N = 277
R-CVP
N = 162
Total
N = 439
p-value
Sex M: 119; 43.0%
F: 158; 57.0%
M: 88; 54.3%
F: 74; 45.7%
M: 207; 47.2%
F: 232; 52.8%
.02
Age > 60 99; 35.7% 41; 25.3% 140; 31.9% .02
Stages I/II: 4; 1.4%
III/IV: 273; 98.6%
I/II: 2; 1.2%
III/IV: 160; 98.8%
I/II: 6; 1.4%
III/IV: 433; 98.6%
.86Journal of Hematology & Oncology 2009, 2:14 http://www.jhoonline.org/content/2/1/14
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R-CVP for CR+PR (96% vs. 81%). Assuming 80% power
using 2-tailed Fisher's Exact test, with significance at p <
0.05, the trial would require about 75 patients per treat-
ment group, not counting replacement of patients with
incomplete data. With this in mind, we conducted the cur-
rent meta-analysis of all relevant literature comparing the
two treatment options, the primary outcome measures
being CR, PR, or CR+PR. Our sources were the commonly
used search engines and the abstracts of the American
Society of Hematology. In the first analysis, comparing R-
CHOP and R-CVP as frontline agents, only two pertinent
articles could be retrieved, whereas four were available for
the second analysis. This paucity of studies underlines the
difficulty inherent in systemically comparing response
rates in patients with indolent diseases treated with two
different but very effective regimens.
As shown in table 4, patients treated with frontline R-CVP
had a much higher chance of developing a CR compared
to those with frontline R-CHOP. However, when com-
bined with studies of relapsed or previously treated
patients, the difference–still favoring R-CVP–became only
marginally significant. One possible explanation for this
result is that the patients treated with R-CHOP had higher
ECOG scores, were older, and were women. On the con-
trary, in both the analyses, the probability of achieving an
overall response (CR or PR) was significantly higher when
patients were treated with R-CHOP as opposed to R-CVP.
With the data presented, it would seem that patients
would fare better overall with R-CHOP, for 96% experi-
enced some form of response in both analyses, signifi-
cantly higher than the 81% found for patients treated with
R-CVP. However it is unclear and we were unable to
obtain usable data to test whether a response of any type
necessarily correlates with increased survival.
Multiple observations need to be made about the present
data. The most obvious is that the definitions for CR and
PR are not uniform across studies. Second, we could
retrieve only one prospective study involving R-CVP [7] in
the treatment of FL. Third, the high CR rates reported by
Czuczman et al. [4] and Domingo-Domenech et al. [6]
were not supported by Hiddemann et al. [5]. In the study
by Czuczman et al. [4] the number of patients treated with
R-CHOP was 38 and in Domingo-Domenech et al. [6]
was 16, approximately 20% of the total patient popula-
tion treated with R-CHOP in our analyses. Hence, the CR
rate from this R-CHOP group was clearly lower than R-
CVP. From the combined data it would seem evident from
both studies that R-CVP was overall inferior to R-CHOP.
Table 3: Main Characteristics of the Analyzed Trials
Study Patient Population Treatment
(N)
CR
(n; %)
PR
(n; %)
OR
(n; %)
Criteria
Czuczman et al [4]: Prospective; Single 
treatment group; Intent to treat trial
N-40; 18 years and older with CD 
20+ follicular lymphoma
R-CHOP
N = 40
22; 55% 16; 40% 38; 95% Table 1
Hiddemann W et al. [5]: Prospective, 
randomized, non-crossover, open label 
multicenter phase 3 trial
N = 428; 18 years and older with 
untreated advanced stage follicular 
lymphoma
R-CHOP
(N = 223)
vs.
CHOP
(N = 205)
44; 20%
35; 17%
170; 77%
150; 73%
214; 96%
185; 90%
IWG[13]
Domingo-Domenech et al. [6]: Prospective, 
non-randomized, non-crossover, open label 
multicenter phase 2 trial
N = 16; 18 to 70 years age with CD 
20+ follicular lymphoma
R-CHOP
(N = 16)
12; 75% 2; 13% 14; 88% IWG [13]
Marcus R et al. [7]: Prospective, randomized, 
non-crossover trial
N = 321; 18 years or older, 
untreated CD 20+ follicular 
lymphoma
R-CVP
(N = 162)
vs.
CVP
(N = 159)
66; 41%
16; 11%
65; 40%
74; 47%
131; 81%
90; 57%
IWG[13]
Table 4: Response of FL to R-CVP and R-CHOP as Frontline Agents
Variable R-CHOP
N = 223
R-CVP
N = 160
p-value
CR (n; %) 44; 19.7% 66; 41.3% < .001
Favors R-CVP
PR (n; %) 170; 76.2% 65; 40.6% < .001
Favors R-CHOP
Total Response (CR+PR)
(n; %)
214; 96.0% 131; 81.9% < .001
Favors R-CHOPJournal of Hematology & Oncology 2009, 2:14 http://www.jhoonline.org/content/2/1/14
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This difference could be from selection bias and non-com-
parability of the study subjects.
No data were located for comparing R-CHOP vs. R-CVP
for relapsed patients with follicular lymphoma, and no
data for previously treated and relapsed patients on R-
CVP. Finally, it was unfortunate that for the second anal-
ysis only age, sex, and stage were reported as demographic
and clinical variables in all four studies. We had to ignore
the values for patients' performance status, bone marrow
involvement, ECOG status, LDH status, B-symptoms, and
IPI because none of these variables was available for all
four studies in the analysis. Editors may wish to require
future studies to report such fundamental variables not
only to satisfy readers' immediate interests but as well
with an eye towards future meta-analyses.
For indolent disease like follicular lymphoma, response
may not be an adequate end-point. Although some recent
studies suggest the importance of CR for survival, the pro-
gression-free survival or time to treatment failure (TTF)
could be more relevant and could avoid the bias of meas-
urement. Marcus et al [7] investigated the addition of
rituximab to CVP (R-CVP) therapy compared with CVP
therapy alone and showed a significant advantage for R-
CVP for remission rate (81% vs. 57%; P < .001), TTF (27
months vs. 7 months; P < .001), and time to next therapy
(median not reached vs. 12 months; P < .001). However,
remission rates and TTF achieved by R-CVP appear com-
parable to the results obtained by CHOP alone. A substan-
tially better outcome seems to be achieved by R-CHOP.
Adverse effects, particularly severe granulocytopenia, were
less frequently encountered after CVP (14%) or R-CVP
(24%) than after CHOP (53%) or R-CHOP (63%).
An unavoidable weakness of any meta-analysis is its ina-
bility to perform multivariate analyses that might throw
light on the importance of various potentially confound-
ing variables for the overall outcome, in ways not avail to
any of the constituent studies because of their limited
sample sizes.
QUOROM provides a system for rating studies to be
included in meta-analyses of randomized clinical trials.
We did not use this system, for we wished to incorporate
all available data. We judged all four cited articles as
equally relevant in providing accurate data for our pur-
poses. Other studies utilizing G-CSF with R-CHOP for the
treatment of FL, such as by Niitsu et al.[15], were excluded
because they attempted to use G-CSF as a treatment
modality, and responses changed depending on the dose
of G-CSF provided. As with any paper, much information
was omitted from our study and one should not use this
article as a crutch when determining the appropriate
chemotherapeutic protocol for a patient. Profiles of side
effects of Adriamycin were not evaluated, nor could we
provide a correlation between specific responses and
length of survival or cost of treatment. One should always
evaluate specific cases when deciding the treatment proto-
col appropriate for the individual.
The international PRIMA study testing the efficacy of
maintenance therapy by rituximab may provide impor-
tant data in the field of the best induction in patients with
follicular lymphoma.
In summary, we conclude that treatment for patients with
FL should be individualized. R-CHOP and R-CVP proto-
cols can both achieve excellent overall response. In
patients with known cardiac history, omission of anthra-
cyclines is reasonable, and R-CVP provides a very good CR
rate. In younger patients with FL where cumulative cardio-
toxicity may be of importance in the long term and in
whom future stem cell transplantation is an option, R-
CVP may be a more appealing option. How the response
rates translate to survival is not known and certainly needs
to be further clarified in prospectively designed long-term
follow-up studies.
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